

## Priority-driven Collaborative Cancer Research Scheme 2010

---

Cancer Australia, *beyondblue:the national depression initiative*; Cancer Council New South Wales, Cancer Council Tasmania, CanTeen, Cure Cancer Australia Foundation, Leukaemia Foundation, National Breast Cancer Foundation, National Centre for Gynaecological Cancers, National Lung Cancer Program, and the Prostate Cancer Foundation of Australia, are pleased to announce that the following applicants have been recommended for funding in the 2010 Round of the Priority-driven Collaborative Cancer Research Scheme:

### **Blackburn, A**

#### **John Curtin School of Medical Research**

*Targeting Of Two Aspects of Metabolism (TOTAM) for cancer therapy*

Co-funded by the National Breast Cancer Foundation and Cancer Australia

### **Chambers, S**

#### **Cancer Council Queensland**

*ProsCan for Life: A Multimodal Supportive Care Intervention for Men with Prostate Cancer*

Co-funded by *beyondblue* and Cancer Australia

### **Chen, Y**

#### **The Children's Hospital at Westmead**

*Tumor protein D52 overexpression and DNA repair in cancer*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

### **Chua, B**

#### **Peter MacCallum Cancer Centre**

*A phase III randomised trial of postmastectomy chest wall irradiation in intermediate risk operable breast cancer*

Funded by Cancer Australia

### **Davidson, A**

#### **University of Sydney – Clinical Trials Centre**

*NITRO - A randomised, phase III trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer*

Funded by Cancer Australia

### **Dobrovic, A**

#### **Peter MacCallum Cancer Centre**

*Identifying therapeutic targets by profiling DNA repair in lung cancer*

Funded by the National Lung Cancer Program

### **Evans, S**

#### **Monash University**

*Determining the causes of observed variation in survival after diagnosis of prostate cancer*

Funded by Cancer Australia

### **Farah, C**

#### **University of Queensland**

*Autofluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers*

Funded by Cancer Australia

### **Fogarty, G**

#### **University of Sydney**

*Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial*

Funded by Cancer Australia

**Friedlander, M**

**Prince of Wales Hospital, Sydney**

*A randomised, placebo-controlled trial of concurrent cediranib [AZD2171] with platinum-based chemotherapy and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer: ICON 6*

Funded by the National Centre for Gynaecological Cancers

**Garland, S**

**University of Melbourne**

*Genetic and environmental factors in invasive cervical cancer: a twin study*

Funded by the National Centre for Gynaecological Cancers

**Halkett, G**

**Curtin University of Technology**

*Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple-baseline study*

Co-funded by *beyondblue* and Cancer Australia

**Henson, J**

**Children's Medical Research Institute**

*Alternative Lengthening of Telomeres (ALT) in lung cancer: analysis of effects on patient outcomes and development of a blood test*

Co-funded by Cure Cancer Australia Foundation and the National Lung Cancer Program

**Hilton, H**

**Westmead Institute for Cancer Research**

*The impact of aberrant progesterone signalling on lineage specification during early malignant transformation*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Lopez, A**

**SA Pathology**

*The role of CD123 in MDS and AML*

Co-funded by the Leukaemia Foundation and Cancer Australia

**McCarroll, J**

**Children's Cancer Institute for Medical Research Australia**

*Targeting Drug Resistant Genes in Brain Cancer: Delivery of siRNA to Improve Cancer Therapy*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**McGregor, S**

**Queensland Institute of Medical Research**

*Identifying markers of risk and outcome in ovarian and breast cancer via efficient evaluation of DNA methylation in peripheral blood*

Co-funded by the National Breast Cancer Foundation and Cancer Australia

**Millar, J**

**Alfred Hospital, Melbourne**

*START: Phase III Study of Active Surveillance Therapy Against Radical Treatment in patients diagnosed with favourable risk prostate cancer*

Co-funded by the Prostate Cancer Foundation of Australia and Cancer Australia

**Mitchell, G**

**Peter MacCallum Cancer Centre**

*Personalised breast cancer risk prediction in BRCA mutation carriers*

Co-funded by the National Breast Cancer Foundation and Cancer Australia

**Mitchell, G**

**Peter MacCallum Cancer Centre**

*Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in BRCA1/2 mutation carriers and controls - The IMPACT study.*

Co-funded by Cancer Council Tasmania and Cancer Australia

**Preen, David**

**The University of Western Australia**

*Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian clinical practice*

Co-funded by the National Breast Cancer Foundation and Cancer Australia

**Sawyer, S**

**Centre for Adolescent Health, Royal Children's Hospital and Department of Paediatrics,  
University of Melbourne**

*Fulfilling the vision of youth-friendly cancer care: How well are we meeting the psychosocial needs of AYA patients?*

Co-funded by *beyondblue*, CanTeen and Cancer Australia

**Spurdle, Amanda**

**Queensland Institute of Medical Research**

*Development of a model to classify mismatch repair gene sequence variants of uncertain clinical significance*

Funded by Cancer Australia

**Tilley, W**

**University of Adelaide**

*A novel approach to predict metastatic potential of prostate cancer at diagnosis*

Funded by Cancer Australia

**Ward, R**

**Lowy Cancer Research Centre**

*Role of dietary compounds on PGC-1 alpha methylation in colorectal cancer*

Funded by Cancer Council New South Wales

**Woods, S**

**Queensland Institute of Medical Research**

*The microRNA miR-211 as a novel tumour suppressor for melanoma: a verification of candidate miR-211 targets involved in neural crest induction, migration and cell polarity.*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

**Youl, P**

**Cancer Council Queensland**

*A multi-level investigation of inequalities in clinical and psychosocial outcomes for women after breast cancer*

Funded by Cancer Australia

**Ziegler, D**

**Sydney Children's Hospital**

*Identification of anti-apoptotic signalling pathways in malignant gliomas*

Co-funded by Cure Cancer Australia Foundation and Cancer Australia